To Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals

A Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy of CitruSlim® on Body Composition as Well as Metabolic and Hormonal Factors in Overweight and Obese Individuals

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03973086

Enrollment

Registered

2019-06-04

Start date

2019-06-04

Completion date

2020-09-18

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obesity

Brief summary

CitruSlim® can promote healthy weight loss by promoting anabolic state during weight loss programs, prevent the body from storing fat, reduce appetites and maintain healthy cholesterol and blood glucose level during weight loss program. This study focuses to prove the efficacy and safety of the product in a population of overweight and obese individual.

Interventions

DIETARY_SUPPLEMENTCitrus flavonone-O-glycosides- LD

Low Dose of 200 mg

DIETARY_SUPPLEMENTCitrus flavonone-O-glycosides- HD

High Dose of 400 mg

DIETARY_SUPPLEMENTPlacebo

Placebo (Microcrystalline Cellulose) of 400 mg

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

1. Male and female participants with the age of ≥18 and ≤ 60 years of age. 2. BMI of ≥25 - ≤ 35 kg/m2 3. Waist circumference:India: Men: \> 94 cm (37 inches), Women: \>80 cm (31.5 inches) USA: Men: \> 102 cm (40 inches), Women: \>89 cm (35 inches) 4. Triglycerides \>150 mg/dL 5. Blood pressure: Systolic: ≥130 mm Hg and/or Diastolic: ≥85 mm Hg 6. Fasting blood glucose ≥ 100 mg/ dl 7. Low HDL level: Men: \< 40 mg/dL, Women: \< 50 mg/dL 8. Ready to give voluntary, written, informed consent to participate in the study.

Exclusion criteria

Participants meeting any of the following criteria will be excluded from the trial: 1. Current smoker. 2. Inability to walk independently. 3. Presence of unstable, acutely symptomatic, or life-limiting illness. 4. Neurological conditions causing functional or cognitive impairments 5. Unwillingness or inability to be randomized to one of three intervention groups. 6. Bilateral hip replacements. 7. Exposure to any non-registered drug product within 3 months prior to the screening visit. 8. Unable/unwillingness to complete study specific diaries (digital/paper-based).

Design outcomes

Primary

Measure	Time frame	Description
Change in body fat percent Body Mass Index (kg/m2)	16 weeks.	Assessed using DEXA
Change in Lean Body Mass (g)	16 weeks	Assessed using DEXA
Change in Body Fat (%)	16 weeks	Assessed using DEXA
Change in Fat Free Mass (g)	16 weeks	Assessed using DEXA

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026